The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: a randomised controlled trial (EAGLE)

HS Grampian0 个研究点目标入组 400 人开始时间: 2008年10月23日最近更新: 2017年2月20日

适应症

试验速览

暂无简介。

•1. Both males and females, age >=50 years
•2. Diagnosis: either one of the following two types of patients: (i) primary angle-closure glaucoma (PACG), or (ii) primary angle-closure (PAC) with intraocular pressure (IOP) >30 mm Hg
•3. Newly diagnosed, i.e. either (i) untreated or (ii) under medical treatment for 6 months or less
•4. Angle closure (iridotrabecular contact) in 180 degrees or more
•5. Patient must be phakic in the affected eye(s)
•6. Written informed consent obtained

•1. Advanced glaucoma in the potentially eligible eye as determined by either: (i) visual field loss (mean deviation worse than -15dB) or (ii) cup-disc-ratio >0.9
•2. Previously diagnosed acute angle closure attack in the potentially eligible eye
•3. Increased surgical risk: e.g., corneal opacity, Fuch's endothelial dystrophy, pseudoexfoliation, previous vitreo-retinal surgery, not able to be positioned to undergo standard technique
•4. Symptomatic cataract in either eye
•5. Previous cataract surgery or laser iridotomy in study eye
•6. Axial length <19 mm (nanophthalmos)
•7. Secondary angle closure glaucoma
•8. History of retinal ischaemia, macular oedema or wet age-related macular degeneration
•9. Medically unfit for surgery or for completion of the trial
•Removed from the protocol as of 04/11/10:
•10. Life expectancy <3 years

发起方

HS Grampian